| Ticker: UFEM | 500 Fifth Avenue, Suite 3620 | |
| Exchange: NASDAQ-National Market | New York, New York 10110 | |
| Industry: Manufacturing | (212) 575-5740 |
| Type of Shares: | Common Shares | Filing Date: | 10/11/95 | |
| U.S. Shares: | 3,400,000 | Offer Date: | 2/22/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $10.00 | |
| Primary Shares: | 3,400,000 | Offer Price: | $10.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.80 | |
| Offering Amount: | $34,000,000 | Selling: | $0.48 | |
| Expenses: | $1,850,830 | Reallowance: | $0.10 | |
| Shares Out After: | 8,281,105 |
| Manager | Tier | Phone |
| Hampshire Securities Corporation | Lead Manager | (212) 444-2144 |
| Auditor: Deloitte & Touche | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/95 | 12/31/95 | 12/31/94 | 12/31/95 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $2.45 |
| Net Income: | -$2.38 | -$3.19 | -$1.25 | Liabilities: | $11.65 |
| EPS: | -$0.87 | -$1.12 | -$0.46 | Equity: | -$9.20 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a development stage company organized in 1990 by a woman specifically to address women's health care needs. The company has developed a feminine hygiene product which represents a significant departure from existing products in terms of design and material composition and which has the potential to be used for multiple feminine health applications. These applications include use as feminine protection product and as a vaginal drug delivery system of agents for contraception, prevention of sexually transmitted diseases, treatment of vaginal infections and topical and systemic therapies. The Feminine Hygiene Product is disposable and is made of a soft, inert, thermoplastic material which becomes more pliable at body temperature and molds to fit the user's anatomy. The company has obtained FDA clearance to market the Feminine Hygiene Product as a feminine protection product in the U.S. |
| Use of Proceeds |
| Proceeds from the offering will be used to repay indebtedness and for expenses relating to the initial introduction of the product, including capital expenditures, pre-launch marketing activities, research and development, and general corporate purposes and working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.